Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1221-1240 of 3,900 trials

Advanced Solid Tumors: Selpercatinib Access Program

We are providing access to selpercatinib for adults with locally advanced or metastatic solid tumors that have specific genetic changes. This program aims to help patients who may benefit from this targeted treatment.

Various Types of Cancer>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Hepatocellular Carcinoma: Durvalumab and Bevacizumab Study

We are studying whether the combination of durvalumab and bevacizumab can help prevent cancer recurrence in patients with hepatocellular carcinoma after surgery or ablation. This trial compares these treatments to a placebo to assess their effectiveness.

Early Stage Liver Cancer>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteHepatologyOncology

Chronic Lymphocytic Leukemia: Pirtobrutinib vs. Ibrutinib

We are comparing the effectiveness of pirtobrutinib to ibrutinib in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This study also focuses on those who are newly diagnosed and have a specific genetic change.

Chronic Lymphocytic Leukemia6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Acute Respiratory Distress Syndrome: PRS CK STORM Treatment

We are testing a new cell therapy to see if it helps patients with acute respiratory distress syndrome caused by viruses like COVID-19 and influenza. The study will evaluate its safety and effectiveness in reducing severe immune responses.

Acute Respiratory Distress Syndrome (ARDS)>2 yearsSafety phase (I)Infectious DiseasesPulmonology

Rheumatoid Arthritis: MethMax Trial

We are studying how well methotrexate works for people with active rheumatoid arthritis. The goal is to see if it helps more patients reach remission or low disease activity compared to current treatments.

Rheumatoid Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Deep Burns: Testing denovoSkin™ Graft

We are studying a new skin graft for patients with deep partial and full-thickness burns to see if it helps wounds heal and reduces scarring better than standard treatments. This trial aims to improve recovery outcomes for burn patients.

Deep Partial and Full-Thickness BurnsConfirmation phase (III)No PlaceboInvestigational MedicinesDermatology

Axial Spondyloarthritis: Risankizumab Treatment

We are studying the effects of a new treatment for patients with very early axial spondyloarthritis. The goal is to see if it can reduce disease activity and improve overall function.

Axial Spondyloarthritis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Frontotemporal Dementia: PBFT02 Treatment Study

We are evaluating a new treatment for adults with Frontotemporal Dementia linked to GRN or C9orf72 mutations. The study aims to understand its safety and how well it works in this specific group.

Frontotemporal DementiaSafety phase (I)Efficacy phase (II)Neurology

B-Cell Non-Hodgkin Lymphoma: Glofitamab Treatment

We are studying a new treatment using Glofitamab after Obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Our goal is to evaluate its safety and effectiveness compared to standard treatments.

B-cell Non-Hodgkin's Lymphoma Refractory>2 yearsSafety phase (I)HematologyOncology

Nasal Treatment: HY-133 Bacteriophage Endolysin

We are testing a new nasal treatment to see if it is safe and effective for patients. This study also explores how it affects the nasal microbiome.

Nasal Colonization with MSSA1-2 yearsSafety phase (I)Infectious DiseasesOtolaryngology

Opioid-Induced Bowel Dysfunction: Naldemedine Study

We are investigating how naldemedine affects bowel function in individuals using opioids like tramadol. The goal is to see if it improves gastrointestinal movement and overall bowel health.

Opioid Induced Bowel Dysfunction≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Hemophilia A: Long-Term Follow-Up of BMN 270

We are investigating the long-term safety and effects of a gene therapy for severe hemophilia A in individuals who participated in a previous study. This includes looking at their quality of life and the need for additional treatments.

Hemophilia A>2 yearsMonitoring phase (IV)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Multiple Myeloma: BGB-11417 Treatment Study

We are investigating the safety and effectiveness of BGB-11417 alone and with other medications for patients with relapsed or refractory multiple myeloma. This study aims to find the best treatment options for those with a specific genetic marker.

Relapsed or Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Progesterone for Preventing Preterm Birth in Women with Placenta Previa

We are studying whether progesterone can help reduce the risk of preterm birth in women diagnosed with placenta previa. This trial will look at various outcomes, including the timing of birth and any side effects for mothers and babies.

Placenta Previa3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsPediatrics

Pancreatic Cancer: Islet Cell Transplantation After Surgery

We are studying the effects of removing part or all of the pancreas and transplanting the patient's own islet cells in patients with pancreatic cancer at high risk for complications. The goal is to see if this approach improves safety and quality of life.

Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Advanced Cancers: MAQ-001 Treatment Study

We are evaluating the safety of MAQ-001, both alone and with other treatments, for patients with advanced cancers. This study aims to understand how well it works in this patient group.

Advanced Cancers Treated with Immune Checkpoint Blockade>2 yearsSafety phase (I)Oncology

MK-1084 with Pembrolizumab for Metastatic Lung Cancer

We are studying a new treatment combination for patients with KRAS G12C-mutant metastatic lung cancer. The goal is to see if it works better than standard treatment in improving survival and quality of life.

Non-small cell lung cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementOncology

Lung Cancer: IPH5201 and Durvalumab Treatment Study

We are studying a combination of two treatments before and after surgery for patients with early-stage non-small cell lung cancer. The goal is to see if this approach improves tumor response and safety compared to standard treatments.

Non-Small Cell Lung Cancer (NSCLC) Stage II and III1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Coronary Artery Spasm: Testing Bosentan

We are studying whether the medication bosentan can help reduce coronary artery spasms in patients with ongoing angina symptoms. The trial also aims to evaluate its effects on quality of life and safety.

Coronary Vasospasm≤3 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

iTTP Treatment: TAK-755 Study

We are testing a new treatment called TAK-755 for patients with immune-mediated thrombotic thrombocytopenic purpura. The study aims to see if it is safe and effective in reducing symptoms and preventing future episodes.

Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP)≤3 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematology